Summarized by Masters of Longevity from Longevity Technology.
This piece previews a short news article about early human safety results for a novel gene‑based eye therapy in glaucoma, inviting readers curious about emerging clinical developments to learn more.
Key Takeaways
- Three adults with open-angle glaucoma received a single intravitreal Dose Level 1 administration combined with daily oral doxycycline.
- No dose-limiting toxicities or treatment-related adverse events were reported through Day 56 after Dose Level 1.
- The Data Safety Monitoring Board recommended escalation to Dose Level 2 and the trial is ongoing.
